Century Therapeutics Investor Presentation — January 2022

Document content

HEALTHCARE CONFERENCE

January 202222FORWARD -LOOKING STATEMENTS

This presentation contains forward -looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements

contained in this document, other than statements of historical facts or statements that relate to present facts or current c ond itions, including but not limited to, statements regarding possible or

assumed future results of operations, business strategies, research and development plans, regulatory activities, market oppo rtunity, competitive position and potential growth opportunities are

forward -looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be

materially different from any future results, performance or achievements expressed or implied by the forward -looking statements . In some cases, you can identify forward -looking statements by terms

such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “projec t,”“contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or

the negative of these terms or other similar expressions. The forward -looking statements in this presentation are only predictio ns. We have based these forward -looking statements largely on our

current expectations and projections about future events and financial trends that we believe may affect our business, financ ialcondition and results of operations. These forward -looking statements

speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of w hich cannot be predicted or quantified and some of which are beyond our

control, including, among others: our ability to successfully advance our current and future product candidates through devel opm ent activities, preclinical studies, and clinical trials; our reliance on the

maintenance on certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including

final regulatory approval of our product candidates; the impact of the COVID -19 pandemic on our business and operations; the per formance of third parties in connection with the development of our

product candidates, including third parties conducting our future clinical trials as well as third -party suppliers and manufacturers; our ability to successfully commercialize our product candidates and

develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfull y enforce adequate intellectual property protection. These and other risks